JPRN-C000000290已完成2 期
Phase II study of imatinib mesylate for treatment of Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children: A Japanese Cooperative Trial - Ph+ ALL04
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)0 个研究点目标入组 56 人开始时间: 2005年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1years-old 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Intracranial hemorrhage. Heart failure requiring treatment. Chronic renal failure. Active uncontrolled infections. Diabetes mellitus. Liver chirrhosis. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent. Female patients who are pregnant or breast-feeding.
研究者
相似试验
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryAcral Lentiginous Malignant MelanomaRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaNCT00470470National Cancer Institute (NCI)30
进行中（未招募）
1 期
Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic LeukemiaPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia (Ph+ALL)EUCTR2017-001805-34-Outside-EU/EEAovartis Pharma K.K20
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage IV Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00041340National Cancer Institute (NCI)37
进行中（未招募）
1 期
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10051066 Term: Gastrointestinal stromal tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-GBEuropean Organisation for Research and Treatment of Cancer76
进行中（未招募）
不适用
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-ESEuropean Organisation for Research and Treatment of Cancer240